Genotypic variations around the world: Is hepatitis C virus evolving?

Current Hepatitis Reports

Volumn 5, Issue 4, 2006, Pages 142-149

  Kamal, Sanaa M ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

CHRONIC LIVER DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE TRANSMISSION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; POPULATION RESEARCH; REVIEW; TREATMENT RESPONSE; VIRUS TRANSMISSION;

EID: 33845939137     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-006-0023-y     Document Type: Review

References (60)

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999, 6:35-47.
2. Seeff LB: Natural history of chronic hepatitis C. Hepatology 2002, 36(5 suppl 1):S35-S46.
3. Alter MJ, Kruszon-Moran D, Nainan OV, et al.: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341:556-562.
4. Wasley A, Alter MJ: Epidemiology of hepatitis C: geographic differences and temporal trends [review]. Semin Liver Dis 2000, 20:1-16.
5. Abdel-Aziz F, Habib M, Mohamed MK, et al.: Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology 2000, 32:111-115.
6. Simmonds P: Viral heterogeneity of the hepatitis C virus. J Hepatol 1999, 31:54-60.
7. Simmonds P: Genetic diversity and evolution of hepatitis C virus-15 years on [review]. J Gen Virol 2004, 85:3173-3188. Comprehensive review of the evolution of HCV infection.
8. Simmonds P, Bukh J, Combet C, et al.: Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42:962-973. Recommendations generated from an international panel of experts in the area of HCV virology concerning a unified system of nomenclature for hepatitis C virus genotypes.
9. Shobokshi OA, Serebour FE, Skakni L, et al.: Hepatitis C genotypes and subtypes in Saudi Arabia. J Med Virol 1999, 58:44-48.
10. Smuts HE, Kannemeyer J: Genotyping of hepatitis C virus in South Africa. J Clin Microbiol 1995, 33:1679-1681.
11. Tokita H, Okamoto H, Luengrojanakul P, et al.: Hepatitis C virus variants from Thailand classifiable into five novel genotypes in the sixth (6b), seventh (7c, 7d) and ninth (9b, 9c) major genetic groups, J Gen Virol 1995, 76:2329-2335.
12. Nguyen MH: Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol 2005, 3(10 Suppl 2):S97-S101.
13. Smith DB, Pathirana S, Davidson F, et al.: The origin of hepatitis C virus genotypes. J Gen Virol 1997, 78:321-328.
14. Jeannel D, Fretz C, Traore Y, et al.: Evidence for high genetic diversity and long-term endemicity of hepatitis C virus genotypes 1 and 2 in West Africa. J Med Virol 1998, 55:92-97.
15. Xu LZ, Larzul D, Delaporte E, et al.: Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon). J Gen Virol 1994, 75:2393-2398.
16. Pybus OG, Charleston MA, Gupta S, et al.: The epidemic behavior of the hepatitis C virus. Science 2001, 292:2323-2325.
17. Ray SC, Arthur RR, Carella A, et al.: Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis 2000, 182:698-707.
18. Pybus OG, Drummond AJ, Nakano T, et al.: The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach. Mol Biol Evol 2003, 20:381-387.
19. Blatt LM, Mutchnick MG, Tong MJ, et al.: Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 2000, 7:196-202.
20. Schutzbank TE, Rasheed S, Kovacs A, et al.: HCV population study in the US: an incentive for further clinical trials [abstract]. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL; September 14-17, 2003. Abstract V-775. Assessment of the genotype distribution in a large cohort of HCV-infected individuals in the United States.
21. Andonov A, Chaudhary RK: Genotyping of Canadian hepatitis C virus isolates by PCR. J Clin Microbiol 1994, 32:2031-2034.
22. Campiotto S, Pinho JR, Carrilho FJ, et al.: Geographic distribution of hepatitis C virus genotypes in Brazil. Braz J Med Biol Res 2005, 38:41-49.
23. Verbeeck J, Maes P, Lemey P, et al.: Investigating the origin and spread of hepatitis C virus genotype 5a. J Virol 2006, 80:4220-4226.
24. Schroter M, Zollner B, Schafer P, et al.: Epidemiological dynamics of hepatitis C virus among 747 German individuals: new subtypes on the advance. J Clin Microbiol 2002, 40:1866-1868.
25. Kalinina O, Norder H, Vetrov T, et al.: Shift in predominating subtype of HCV from 1b to 3a in St. Petersburg mediated by increase in injecting drug use. J Med Virol 2001, 65:517-524.
26. Payan C, Roudot-Thoraval F, Marcellin P, et al.: Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat 2005, 12:405-413.
27. Sanchez-Quijano A, Abad MA, Torronteras R, et al.: Unexpected high prevalence of hepatitis C virus genotype 4 in Southern Spain. J Hepatol 1997, 27:25-29.
28. Katsoulidou A, Sypsa V, Tassopoulos NC, et al.: Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. J Viral Hepat 2006, 13:19-27.
29. Guadagnino V, Stroffolini T, Rapicetta M, et al.: Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 1997, 26:1006-1011.
30. Hissar SS, Goyal A, Kumar M, et al.: Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease. J Med Virol 2006, 78:452-458.
31. Zein NN: Clinical significance of hepatitis C virus genotypes [review]. Clin Microbiol Rev 2000, 13:223-235.
32. Pawlotsky JM: Hepatitis C virus genetic variability: pathogenic and clinical implications [review]. Clin Liver Dis 2003, 7:45-66. A review of the impact of HCV genotype variability on the clinical and histologic manifestations of liver disease.
33. Kamal SM, Fouly AE, Kamel RR, et al.: Peginterferon alfa-2b therapy in acute hepatitis: impact of onset of therapy on sustained virologic response. Gastroenterology 2006, 130:632-638.
34. Lehmann M: High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol 2004, 73:387-391.
35. Zein NN, Poterucha JJ, Gross JB Jr, et al.: Increased risk of hepatocellular carcinoma in patients infected with hepatitis C genotype 1b. Am J Gastroenterol 1996, 91:2560-2562.
36. Serra MA, Rodriguez F, del Olmo JA, et al.: Influence of age and date of infection on distribution of hepatitis C virus genotypes and fibrosis stage. J Viral Hepat 2003, 10:183-188.
37. Kamal SM, Turner B, He Q, et al.: Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology 2006, 43:771-779. A prospective, longitudinal study, the first to provide comprehensive, long-term follow-up (12 years) of patients infected with HCV G4 starting from the acute phase.
38. Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
39. Fried MW, Shiffman ML, Reddy KR, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
40. Hadziyannis SJ, Sette H Jr, Morgan TR, et al.: PEGASYS International Study Group: Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
41. Berg T, von Wagner M, Nasser S, et al.: Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006, 130:1086-1097.
42. Zeuzem S, Buti M, Ferenci P, et al.: Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006, 44:97-103.
43. Leandro G, Mangia A, Hui J, et al.; HCV Meta-Analysis (on) Individual Patients' Data Study Group: Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006, 130:1636-1642. Analysis of the relationship between genotypes, steatosis, and the progression of fibrosis.
44. Mangia A, Santoro R, Minerva N, et al.: Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005, 352:2609-2617.
45. Brown RS, Jacobson IM, Afdhal N, et al.: Differences in treatment outcome to antiviral therapy based on genotype and viral load in hepatitis C genotypes 2 and 3 in the WIN-R trial [abstract]. Presented at Digestive Disease Week 2006. Los Angeles, CA; May 20-25, 2006. Abstract 523. Preliminary data from one of the largest prospective, randomized, controlled studies in the United States using pegylated IFN and ribavirin.
46. Kamal S, Madwar M, Bianchi L, et al.: Clinical, virological and histopathological features: long-term follow-up in patients with chronic hepatitis C co-infected with S. mansoni. Liver 2000, 20:281-289.
47. Wali MH, Heydtmann M, Harrison RF, et al.: Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4. Liver Transpl 2003, 9:796-804.
48. Zylberberg H, Chaix ML, Brechet C: Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-α [letter]. Ann Intern Med 2000, 132:845-846.
49. Kamal SM, Madwar MA, Peters T, et al.: Interferon therapy in patients with chronic hepatitis C and schistosomiasis. J Hepatol 2000, 32:172-174.
50. Kamal SM, El Tawil AA, Nakano T, et al.: Peginterferon α-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005, 54:858-866. The largest randomized study assessing the efficacy and duration of therapy with combined PEG-IFN and ribavirin in chronic HCV G4.
51. Diago M, Hassanein T, Rodes J, et al.: Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-α2a and ribavirin [letter]. Ann Intern Med 2004, 140:72-73.
52. Alfaleh FZ, Hadad Q, Khuroo MS, et al.: Peginterferon α-2b plus ribavirin compared with Interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004, 24:568-574.
53. Hasan F, Asker H, Al-Khaldi J, et al.: Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004, 99:1733-1737.
54. Legrand-Abravanel F, Nicot F, Boulestin A, et al.: Pegylated Interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J Med Virol 2005, 77:66-69.
55. Khuroo MS, Khuroo MS, Dahab ST: Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4. Aliment Pharmacol Ther 2004, 20:931-938.
56. Roulot DB, Fantain H, Bailly F, et al.; Observational VHC4 Study Group: Epidemiology and response to treatment in patients infected by HCV genotype 4 in France compared to immigrant patients infected in Egypt [abstract]. Hepatology 2004, 40:330A.
57. Serpaggi J, Chaix ML, Batisse D, et al.: Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS 2006, 20:233-240.
58. Bonny C, Roche C, Randl K, et al.: Treatment of interferon-naïve patients with HCV genotype 5 with Interferon (or PEG-interferon) plus ribavirin results in a very high sustained virological response [abstract]. J Hepatol 2003, 38:738A. Data on the response to therapy of HCV G5, about which data are scarce.
59. Hui CK, Yuen MF, Sablon E, et al.: Interferon and ribavirin therapy for chronic hepatitis C virus genotype 6: a comparison with genotype 1. J Infect Dis 2003, 187:1071-1074.
60. Nguyen MH, Trinh HN, Keeffe EB: Evaluation and outcomes of combination therapy with interferon or peginterferon plus ribavirin in 67 Southeast Asian patients with hepatitis C genotypes 6, 7, 8, and 9 [abstract]. Hepatology 2003, 38:644A.